Novavax, Inc. reports results for the quarter ended September 30 - Earnings Summary

Novavax

05/11/2026 18:04

Novavax, Inc. NVAX.OQ reported a quarterly adjusted loss of 19 cents​​ per share for the quarter ended September 30, higher than the same quarter last year, when the company reported EPS of $-1.25.  The mean expectation of seven analysts for the quarter was for a loss of 35 cents per share. Wall Street expected results to range from -49 cents to -23 cents per share.
Revenue fell 3% to $68.30 million from a year ago; analysts expected $50.43 million. 
Novavax, Inc.'s reported EPS for the quarter was a loss of 19 cents​.
The company reported a quarterly loss of $31.38 million.
Novavax, Inc. shares had fallen by 1.5% this quarter and gained 58.5% so far this year.
FORECAST CHANGES
The mean earnings estimate of analysts had fallen by about 104.4% in the last three months.​ 
In the last 30 days, four analysts negatively revised earnings estimates
RECOMMENDATIONS
The current average analyst rating on the shares is "hold" and the breakdown of recommendations is 5 "strong buy" or "buy," 1 "hold" and 3 "sell" or "strong sell." The average consensus recommendation for the biotechnology & medical research peer group is  "buy."
Wall Street's median 12-month price target for Novavax, Inc. is $11.00, about 3.2% above its last closing price of $10.65
This summary was machine generated from LSEG data November 5 at 06:04 p.m. UTC. ​All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)
QUARTER ENDING
ESTIMATE 
ACTUAL
BEAT, MET, MISSED
Sep. 30 2026 
-0.35
-0.19
Beat
Jun. 30 2026 
-0.39
-0.32
Beat
Mar. 31 2026 
-0.23
-0.06
Beat
Dec. 31 2025 
-0.49
0.11
Beat